Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 1
2014 1
2016 1
2017 1
2018 1
2019 1
2021 4
2022 2
2023 4
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

15 results

Results by year

Filters applied: . Clear all
Page 1
More- Versus Less-Intensive Lipid-Lowering Therapy.
Toyota T, Morimoto T, Yamashita Y, Shiomi H, Kato T, Makiyama T, Nakagawa Y, Saito N, Shizuta S, Ono K, Kimura T. Toyota T, et al. Circ Cardiovasc Qual Outcomes. 2019 Aug;12(8):e005460. doi: 10.1161/CIRCOUTCOMES.118.005460. Epub 2019 Aug 15. Circ Cardiovasc Qual Outcomes. 2019. PMID: 31412729
Efficacy of second-line chemotherapy after treatment with gemcitabine plus nab-paclitaxel or FOLFIRINOX in patients with metastatic pancreatic cancer.
Fukahori M, Okabe Y, Shimokawa M, Otsuka T, Koga F, Ueda Y, Nakazawa J, Komori A, Otsu S, Arima S, Makiyama A, Taguchi H, Honda T, Ushijima T, Miwa K, Shibuki T, Nio K, Ide Y, Ureshino N, Mizuta T, Mitsugi K, Shirakawa T. Fukahori M, et al. Sci Rep. 2023 Nov 8;13(1):19399. doi: 10.1038/s41598-023-46924-0. Sci Rep. 2023. PMID: 37938630 Free PMC article.
KUS121, a VCP modulator, has an ameliorating effect on acute and chronic heart failure without calcium loading via maintenance of intracellular ATP levels.
Tsuji S, Otani C, Horie T, Watanabe S, Baba O, Sowa N, Ide Y, Kashiwa A, Makiyama T, Imai H, Nakashima Y, Yamasaki T, Xu S, Matsushita K, Suzuki K, Zou F, Kume E, Hasegawa K, Kimura T, Kakizuka A, Ono K. Tsuji S, et al. Biomed Pharmacother. 2024 Jan;170:115850. doi: 10.1016/j.biopha.2023.115850. Epub 2023 Dec 12. Biomed Pharmacother. 2024. PMID: 38091636 Free article.
C-reactive protein/albumin ratio is the most significant inflammatory marker in unresectable pancreatic cancer treated with FOLFIRINOX or gemcitabine plus nab-paclitaxel.
Shirakawa T, Makiyama A, Shimokawa M, Otsuka T, Shinohara Y, Koga F, Ueda Y, Nakazawa J, Otsu S, Komori A, Arima S, Fukahori M, Taguchi H, Honda T, Shibuki T, Nio K, Ide Y, Ureshino N, Mizuta T, Mitsugi K, Akashi K, Baba E. Shirakawa T, et al. Sci Rep. 2023 May 31;13(1):8815. doi: 10.1038/s41598-023-34962-7. Sci Rep. 2023. PMID: 37258608 Free PMC article.
Acute Lymphocytic Myocarditis With Anti-PD-1 Antibody Nivolumab.
Tadokoro T, Keshino E, Makiyama A, Sasaguri T, Ohshima K, Katano H, Mohri M. Tadokoro T, et al. Circ Heart Fail. 2016 Oct;9(10):e003514. doi: 10.1161/CIRCHEARTFAILURE.116.003514. Circ Heart Fail. 2016. PMID: 27650418 No abstract available.
Gemcitabine plus nab-paclitaxel in older patients with metastatic pancreatic cancer: A post-hoc analysis of the real-world data of a multicenter study (the NAPOLEON study).
Koga F, Kawaguchi Y, Shimokawa M, Murayama K, Nakashita S, Oza N, Ureshino N, Takahashi H, Ueda Y, Nakazawa J, Komori A, Otsu S, Arima S, Fukahori M, Makiyama A, Taguchi H, Honda T, Shibuki T, Nio K, Ide Y, Mizuta T, Shirakawa T, Otsuka T, Mitsugi K. Koga F, et al. J Geriatr Oncol. 2022 Jan;13(1):82-87. doi: 10.1016/j.jgo.2021.06.011. Epub 2021 Jun 29. J Geriatr Oncol. 2022. PMID: 34215525
Scoring model with serum albumin and CA19-9 for metastatic pancreatic cancer in second-line treatment: results from the NAPOLEON study.
Komori A, Otsu S, Shimokawa M, Otsuka T, Koga F, Ueda Y, Nakazawa J, Arima S, Fukahori M, Okabe Y, Makiyama A, Taguchi H, Honda T, Shibuki T, Nio K, Ide Y, Ureshino N, Mizuta T, Shirakawa T, Mitsugi K. Komori A, et al. Int J Clin Oncol. 2023 Aug;28(8):1073-1081. doi: 10.1007/s10147-023-02354-6. Epub 2023 May 20. Int J Clin Oncol. 2023. PMID: 37209158
Phase II study of trifluridine/tipiracil plus bevacizumab by RAS mutation status in patients with metastatic colorectal cancer refractory to standard therapies: JFMC51-1702-C7.
Takahashi T, Yamazaki K, Oki E, Shiozawa M, Mitsugi K, Makiyama A, Nakamura M, Ojima H, Kagawa Y, Matsuhashi N, Okuda H, Asayama M, Yuasa Y, Shimada Y, Manaka D, Watanabe J, Oba K, Yoshino T, Yoshida K, Maehara Y. Takahashi T, et al. ESMO Open. 2021 Apr;6(2):100093. doi: 10.1016/j.esmoop.2021.100093. Epub 2021 Mar 19. ESMO Open. 2021. PMID: 33744811 Free PMC article. Clinical Trial.
Correction to: A multicenter propensity score analysis of FOLFIRINOX vs gemcitabine plus nab-paclitaxel administered to patients with metastatic pancreatic cancer: results from the NAPOLEON study.
Otsuka T, Shirakawa T, Shimokawa M, Koga F, Kawaguchi Y, Ueda Y, Nakazawa J, Komori A, Otsu S, Arima S, Fukahori M, Okabe Y, Makiyama A, Taguchi H, Honda T, Shibuki T, Nio K, Ide Y, Mizuta T, Mitsugi K, Ureshino N. Otsuka T, et al. Int J Clin Oncol. 2021 May;26(5):951-953. doi: 10.1007/s10147-021-01880-5. Int J Clin Oncol. 2021. PMID: 33656656 No abstract available.
15 results